In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival
Main Authors: | Bicaku, E, Xiong, Y, Marchion, D C, Chon, H S, Stickles, X B, Chen, N, Judson, P L, Hakam, A, Gonzalez-Bosquet, J, Wenham, R M, Apte, S M, Fulp, W, Cubitt, C L, Chen, D-T, Lancaster, J M |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388569/ |
Similar Items
-
A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth
by: MARCHION, DOUGLAS C., et al.
Published: (2013) -
BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin
by: Bansal, Nisha, et al.
Published: (2012) -
Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel
by: CHEN, NING, et al.
Published: (2014) -
Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers
by: Hye Sook Chon, et al.
Published: (2017-06-01) -
Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non–small cell lung cancer
by: Liew, Mun Sem, et al.
Published: (2013)